0.32
+0.0075(+2.38%)
Currency In USD
| Previous Close | 0.32 |
| Open | 0.33 |
| Day High | 0.34 |
| Day Low | 0.31 |
| 52-Week High | 2.34 |
| 52-Week Low | 0.28 |
| Volume | 1.16M |
| Average Volume | 1.21M |
| Market Cap | 52.49M |
| PE | -0.34 |
| EPS | -0.95 |
| Moving Average 50 Days | 0.58 |
| Moving Average 200 Days | 0.73 |
| Change | 0.01 |
If you invested $1000 in Renovaro Biosciences Inc. (RENB) since IPO date, it would be worth $54.78 as of May 13, 2025 at a share price of $0.323. Whereas If you bought $1000 worth of Renovaro Biosciences Inc. (RENB) shares 5 years ago, it would be worth $76.05 as of May 13, 2025 at a share price of $0.323.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs
GlobeNewswire Inc.
Apr 22, 2025 1:20 PM GMT
LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven precision Medicine Company that leverages AI platforms to improve outcomes for cancer and neurologically challenged patients, today announced is expanding ou
Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine
GlobeNewswire Inc.
Apr 09, 2025 1:25 PM GMT
Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio l
Renovaro Provides Update to Definitive Agreement with Predictive Oncology
GlobeNewswire Inc.
Apr 04, 2025 1:40 PM GMT
LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today provided an update regarding its Def